APA (7th ed.) Citation

TJ, G., JD, R., CE, D., R, K., A, F., CL, P., & C, K. (2026). Emapalumab for Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome Following CD19-Directed CAR-T in Two Patients With B-ALL: Clinical and Biomarker Correlates. Pediatric blood & cancer, 73(8), e70406. https://doi.org/10.1002/1545-5017.70406

Chicago Style (17th ed.) Citation

TJ, Galletta, Rubinstein JD, Dandoy CE, Khoury R, Faulhaber A, Phillips CL, and Krupski C. "Emapalumab for Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome Following CD19-Directed CAR-T in Two Patients With B-ALL: Clinical and Biomarker Correlates." Pediatric Blood & Cancer 73, no. 8 (2026): e70406. https://doi.org/10.1002/1545-5017.70406.

MLA (9th ed.) Citation

TJ, Galletta, et al. "Emapalumab for Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome Following CD19-Directed CAR-T in Two Patients With B-ALL: Clinical and Biomarker Correlates." Pediatric Blood & Cancer, vol. 73, no. 8, 2026, p. e70406, https://doi.org/10.1002/1545-5017.70406.